FPI-1434 is a monoclonal antibody conjugated commercialized by Fusion Pharmaceuticals, with a leading Phase II program in Cervical Cancer. According to Globaldata, it is involved in 3 clinical trials, of which 1 is ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of FPI-1434s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for FPI-1434 is expected to reach an annual total of $85 mn by 2039 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
FPI-1434 Overview
FP1-1434 is under development for the treatment of solid tumors, colorectal cancer, lung cancer, head and neck cancer squamous cell carcinoma, endometrial cancer, cervical cancer, ovarian cancer, triple-negative breast cancer, adrenocortical carcinoma (adrenal cortex cancer), uveal melanoma, human epidermal growth factor receptor 2 negative breast cancer, Ewing sarcoma and epidermoid carcinoma. The drug is a radionuclide drug conjugate (RDC) which contains monoclonal antibody conjugated to alpha particle-emitting cytotoxic isotope Actinium-225. It is administered through parenteral route. The therapeutic candidate acts by targeting cells expressing insulin-like growth factor-1 receptor (IGF-1R). It is developed based on Fusion’s fast-clear linker technology.
Fusion Pharmaceuticals Overview
Fusion Pharmaceuticals, a subsidiary of AstraZeneca Plc, is a clinical-stage biopharmaceutical company that develops targeted alpha-particle radio therapeutics for the treatment of cancers. It offers pipeline products such as FPI-1434, FPI-2059, FPI-2265 and FPI-1434. The companys pipeline products treat multiple cancers like head and neck bladder cancer, colorectal cancer and gastric cancers. Fusion Pharmaceuticals carters its products under brand Keytruda. It operates in the US and Canada. Fusion Pharmaceuticals is headquartered in Hamilton, Ontario, Canada.
For a complete picture of FPI-1434s valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.